Medical Devices Pipeline Assessment on Clinical Chemistry Rapid Tests and POC

December 9, 2020

Medical devices pipeline assessment on clinical chemistry rapid tests and POC report is now available through Research and Markets. This report provides comprehensive information about the Clinical Chemistry Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Clinical chemistry rapid tests provide the test results immediately. These tests are used in low resource settings with the help of test strips, tablets and solutions.

Scope

  • Extensive coverage of the Clinical Chemistry Rapid Tests & POC under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Clinical Chemistry Rapid Tests & POC and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Clinical Chemistry Rapid Tests & POC under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Products under Development

3.1 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Stage of Development

3.2 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Territory

3.3 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Regulatory Path

3.4 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Estimated Approval Date

3.5 Clinical Chemistry Rapid Tests & POC – Ongoing Clinical Trials

4 Clinical Chemistry Rapid Tests & POC – Pipeline Products under Development by Companies

4.1 Clinical Chemistry Rapid Tests & POC Companies – Pipeline Products by Stage of Development

4.2 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Stage of Development

5 Clinical Chemistry Rapid Tests & POC Companies and Product Overview

6 Clinical Chemistry Rapid Tests & POC- Recent Developments

7 Appendix

7.1 Methodology

7.2 About the Publisher

7.3 Contact

Companies Mentioned

  • Abreos Biosciences Inc
  • Acetaminophen Toxicity Diagnostics, LLC
  • Affinergy LLC
  • Am Biotechnologies, LLC
  • AnaZyme LLC
  • Angle Biosciences Inc
  • Atonomics A/S
  • Augurix SA
  • Baebies Inc
  • Base Pair Biotechnologies Inc
  • Biocross SL
  • Bioftalmik Applied Research
  • Biotech Resources Aust Pty Ltd
  • Boditech Med Inc
  • Burnet Institute
  • Carclo Diagnostic Solutions Ltd
  • CardioGenics Inc
  • Cellex Inc
  • Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine
  • Claremont BioSolutions
  • Columbia University
  • CTK Biotech Inc
  • DiaSys Diagnostic Systems GmbH
  • Edan Instruments Inc
  • Enesi Pharma Ltd
  • Enigma Diagnostics Ltd (Inactive)
  • Erytech Pharma SA
  • FK-Biotecnologia SA
  • Foundation for Innovative New Diagnostics
  • Gendiag
  • Group K Diagnostics
  • Instrumentation Laboratory Co
  • Integrated Diagnostics Inc (Inactive)
  • IntraMed Diagnostics, LLC
  • IPI Singapore
  • Iron Horse Diagnostics, Inc.
  • Kenyatta University
  • Massachusetts Institute of Technology
  • Medical University of South Carolina
  • Monash University
  • Montana State University
  • NanoSpeed Diagnostics Inc
  • Novartis AG
  • Ohmx Corp
  • OPKO Health Inc
  • Oxford Immunotec Ltd
  • P2D Inc
  • Pennsylvania State University
  • Philips Healthcare
  • Pop Test LLC
  • PortaScience Inc
  • ProciseDx LLC
  • Quidel Corp
  • SaltCheck Inc (Inactive)
  • Seattle Children’s Hospital
  • SenGenix Inc
  • SuperNova Diagnostics, Inc.
  • Systagenix Wound Management Ltd
  • The University of New South Wales press Limited
  • Thermo Fisher Scientific Inc
  • Trivitron Healthcare Pvt Ltd
  • True Diagnostics Inc
  • Universal Biosensors Inc
  • University of Edinburgh
  • University of South Australia
  • UrSure Inc

 

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.